Tom Rolf

A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults.

R. Coler, S. Reed, C. Casper, 2019, Vaccine.

A structure-function approach to optimizing TLR4 ligands for human vaccines

G. Ireton, R. Coler, S. Reed, 2016, Clinical & translational immunology.

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

R. Walker, R. Coler, S. Reed, 2018, npj Vaccines.

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE

R. Coler, S. Reed, L. Jayashankar, 2015, Clinical & translational immunology.

Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.

A. Sette, R. Coler, S. Reed, 2020, The Lancet. Respiratory medicine.

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

R. Walker, R. Coler, S. Reed, 2018, npj Vaccines.